BioNTech (BNTX) on Friday announced separate agreements with the US National Institutes of Health and the University of Pennsylvania to settle royalty claims related to sales of its COVID-19 ...

Penn will receive $467 million under a settlement with German drug manufacturer BioNTech, which partnered with Pfizer to develop a COVID vaccine that relied on mRNA technology developed at the ...

BioNTech's Q4 2024 revenue surpassed estimates, totaling 1.19 billion euros. EPS reached 1.08 euros, vastly exceeding the expected 0.42 euros, showcasing strong earnings management. Revenue from ...

BofA lowered the firm’s price target on BioNTech (BNTX) to $143 from $147 and keeps a Buy rating on the shares after the company reported quarterly results, with FY24 COVID revenues coming in ...

BioNTech is the Marketing Authorisation Holder for BNT162b2 (Original) and BNT162b2 Bivalent (Original/Omicron BA.4/BA.5) in the US, EU, UK, Canada, and other countries.

It would be easy to forget that back in 2019, BioNTech was an early-stage biotech firmly focused on cancer vaccines, before being catapulted onto the world-stage with its COVID-19 shot.

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you.